- Home
- DSGN vs OXSQ Comparison
DSGN vs OXSQ Comparison
Compare DSGN & OXSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- OXSQ
- Stock Information
- Founded
- DSGN 2017
- OXSQ 2003
- Country
- DSGN United States
- OXSQ United States
- Employees
- DSGN N/A
- OXSQ N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- OXSQ Blank Checks
- Sector
- DSGN Health Care
- OXSQ Finance
- Exchange
- DSGN Nasdaq
- OXSQ Nasdaq
- Market Cap
- DSGN 224.8M
- OXSQ 190.1M
- IPO Year
- DSGN 2021
- OXSQ N/A
- Fundamental
- Price
- DSGN $3.50
- OXSQ $2.46
- Analyst Decision
- DSGN Hold
- OXSQ
- Analyst Count
- DSGN 1
- OXSQ 0
- Target Price
- DSGN $4.00
- OXSQ N/A
- AVG Volume (30 Days)
- DSGN 140.5K
- OXSQ 425.8K
- Earning Date
- DSGN 05-07-2025
- OXSQ 04-25-2025
- Dividend Yield
- DSGN N/A
- OXSQ 17.04%
- EPS Growth
- DSGN N/A
- OXSQ N/A
- EPS
- DSGN N/A
- OXSQ N/A
- Revenue
- DSGN N/A
- OXSQ $42,166,831.00
- Revenue This Year
- DSGN N/A
- OXSQ $8.73
- Revenue Next Year
- DSGN N/A
- OXSQ N/A
- P/E Ratio
- DSGN N/A
- OXSQ N/A
- Revenue Growth
- DSGN N/A
- OXSQ N/A
- 52 Week Low
- DSGN $2.60
- OXSQ $2.28
- 52 Week High
- DSGN $7.77
- OXSQ $3.28
- Technical
- Relative Strength Index (RSI)
- DSGN 42.85
- OXSQ 42.69
- Support Level
- DSGN $3.23
- OXSQ $2.44
- Resistance Level
- DSGN $5.04
- OXSQ $2.48
- Average True Range (ATR)
- DSGN 0.48
- OXSQ 0.05
- MACD
- DSGN -0.05
- OXSQ 0.00
- Stochastic Oscillator
- DSGN 15.06
- OXSQ 18.75
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About OXSQ Oxford Square Capital Corp.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing, and Diversified Insurance.